HIQA Publishes Health Technology Assessment of RSV Immunisation in Ireland (hiqa.ie)

• RSV causes over 7,000 infections annually in Ireland, with high hospitalisation rates in infants and older adults.
• Immunisation with maternal vaccines or monoclonal antibodies is effective but costly, with five-year budgets up to €58.5 million for infants.
• For adults aged 80+, vaccination is only cost-effective at a vaccine price of €20.

"Ireland's Health Information and Quality Authority (HIQA) has published a health technology assessment (HTA) on RSV immunisation, examining strategies for infants and older adults. For infants, maternal vaccines and monoclonal antibodies are effective, with estimated five-year costs ranging from €15.6 million to €58.5 million. For adults aged 80+, vaccination would cost €70.6 million over five years but is only cost-effective if the vaccine price drops to €20. The HTA highlights the significant disease burden of RSV and the challenge of balancing health benefits with finite budgets."